云南省大姚县归因于肥胖的高血压疾病经济负担研究

摘要:目的　分析云南省大姚县归因于肥胖的高血压疾病经济负担。方法　采用多阶段分层随机抽样方法，抽取该地区≥35岁农村居民2479名进行问卷调查和体格检查。采用二步模型法估算高血压的直接经济负担，采用人力资本法估算其间接经济负担。结果　大姚县高血压、肥胖和中心性肥胖的患病率分别为40.4%、4.6%和39.9%；其中男性分别为40.6%、4.4%、29.9%；女性分别为40.2%、4.9%、49.3%；女性中心性肥胖率明显高于男性（P＜0.01）。高血压的患病率和中心性肥胖率随年龄的增加而上升，随文化程度和人均年收入的增加而下降（P＜0.01）；肥胖者和中心性肥胖者患高血压的风险均明显高于非肥胖者和非中心肥胖者（P＜0.01）。大姚县高血压的人均直接和间接经济负担分别为6802.2元和64.1元；总疾病经济负担为784百万元，其中归因于肥胖和中心性肥胖的高血压疾病经济负担分别为37.6百万元和286.1百万元。结论　归因于肥胖和中心性肥胖的高血压疾病经济负担对当地经济影响显著。应采取措施减少当地肥胖和中心性肥胖的发生，从而降低其导致的经济负担。

Economic burden of hypertension attributable to obesity in DaYao County,Yunnan Province

Abstract: Objective To estimate the economic burden of hypertension attributable to obesity in DaYao County of Yunnan Province. Methods Multistage stratified random sampling method was adopted to select 2479 rural residents aged 35 years and older from DaYao County. Two-step model was used to measure direct economic burden of hypertension, whereas human capital approach was applied to measure indirect economic burden. Results In the study region, the overall prevalences of hypertension, obesity and central obesity were 40.4%, 4.6% and 39.9%, respectively. The prevalence of hypertension, obesity and central obesity were 40.6%, 4.4% and 29.9% among males, whereas 40.2%, 4.9% and 9.3% among females.The prevalences of hypertension and central obesity increased with age, which decreased with level of education and annual per capital income. Obese and central obese people had obviously higher risk of being hypertensive than their counterparts (P<0.01).The per capita direct, indirect and total costs of hypertension were 6802.2Yuan, 64.1Yuan and 784.0 million Yuan, respectively. The cost of hypertension attributable to obesity and central obesity was 37.6 million Yuan and 286.1 million Yuan. Conclusion The costs of hypertension attributable to obesity and central obesity have high economic impact on society in Da Yao County. Effective measures are needed to reduce the prevalence of obesity and central obesity, so as to decrease its related economic burden of disease.